Although MAO treatment did not affect overall CCND1 levels, the introduction of MAO into prostate cancer cells effectively suppressed the splicing events of CCND1a and upregulated CCND1b transcripts in a dose-dependent manner, and eventually led to increased prostate cancer cell proliferation and invasion (Fig. 6b). The gene discussed is CCND1; the disease is prostate carcinoma.